Silo Pharma Inc. (NASDAQ: SILO) announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering SPC-15, its lead intranasal therapeutic targeting post-traumatic stress disorder (PTSD). The invention, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” includes composition and method claims related to the company’s proprietary therapeutic approach to preventing or delaying stress-induced behavioral responses. A corresponding patent was issued by the Japan Patent Office earlier this year.
A Notice of Allowance indicates that the USPTO has completed its examination and determined that the application meets the requirements for patentability and should be granted shortly. Silo said the U.S. patent protection is an important component of its strategy as it advances SPC-15 development for PTSD, adding to its biopharmaceutical intellectual property portfolio of issued and allowed patents. To view the full press release, visit https://ibn.fm/Hh4Z6.
PTSD is a debilitating mental health condition that affects millions of people worldwide, often arising after exposure to traumatic events. Current treatment options include psychotherapy and antidepressants, but many patients do not achieve adequate relief, underscoring the need for new therapeutic approaches. SPC-15 is designed to be administered intranasally, potentially offering a more targeted and rapid way to prevent or reduce stress-induced fear, depressive-like and anxiety-like behaviors. By securing U.S. patent protection, Silo Pharma aims to strengthen its competitive position and support the continued development of SPC-15 through preclinical and clinical stages.
The Notice of Allowance is a significant milestone for Silo Pharma and the broader biotechnology sector focused on central nervous system (CNS) disorders. It provides the company with exclusive rights to the claimed invention in the United States once the patent is granted, which can be crucial for attracting investment and partnerships. For readers, this development signals progress in addressing an underserved condition, as PTSD remains a major public health challenge with limited effective treatments. The patent allowance also adds to Silo’s growing intellectual property portfolio, which includes programs such as SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
Industry analysts often view patent allowances as validation of a company’s innovation and a step toward commercialization. For Silo Pharma, the U.S. patent allowance for SPC-15 could accelerate its development timeline and enhance its ability to secure funding. The company’s focus on stress-induced psychiatric disorders, chronic pain, and CNS diseases aligns with a growing demand for novel therapies in areas with high unmet need. As the patent is expected to be granted shortly, stakeholders will be watching for further updates on SPC-15’s progress. The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO.
BioMedWire (BMW) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN, and a full array of tailored corporate communications solutions. For more information, please visit https://www.BioMedWire.com.
